HMNC Brain Health to Participate in H.C. Wainwright Bioconnect Conference in January 2022

January 6, 2022

MUNICH, Germany, Jan. 06, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “Company”), a clinical stage precision psychiatry biopharma company, pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today that HMNC’s management team will present virtually at the H.C. Wainwright Bioconnect Conference taking place on January 10-13, 2022.

A recording of HMNC’s presentation will be available beginning Monday, January 10th at 7:00 a.m. Eastern Time and is accessible through the following webcast link: The webcast recording will be available via the above link for 90 days.

To schedule a one-on-one meeting with HMNC’s management team, please contact KCSA Strategic Communications at

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates. The Company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). The Company has operations in Germany with plans to open operations in the United States in the near future and is backed by a renowned global venture capital firm, several family offices and a strategic healthcare investor. The Company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

Media Contacts
Alexander Schmidt (Europe)
+49 151 22 99 39 765

Anne Donohoe (U.S.)
+1 212-896-1265

Investor Contact (U.S.)
Tim Regan
+1 347-487-6788

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.